ONO-1110

Phase 2Small molecule

Ono Pharmaceutical Co. Ltd

ONO-1110 is one of 187 small molecule programs targeting Interstitial Cystitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

186

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial CystitisActive, not recruiting

Social Anxiety DisorderActive, not recruiting

Postherpetic NeuralgiaActive, not recruiting

FibromyalgiaActive, not recruiting

Major Depressive DisorderActive, not recruiting

Major Depressive Disorder (MDD)Completed

Hunner Type Interstitial CystitisCompleted

Social Anxiety Disorder (SAD)Completed

Interstitial CystitisPhase 2

Active, not recruiting

Social Anxiety DisorderPhase 2

Active, not recruiting

Postherpetic NeuralgiaPhase 2

Active, not recruiting

FibromyalgiaPhase 2

Active, not recruiting

Major Depressive DisorderPhase 2

Active, not recruiting

Major Depressive Disorder (MDD)Phase 2

Completed

Hunner Type Interstitial CystitisPhase 2

Completed

Social Anxiety Disorder (SAD)Phase 2

Completed

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Elavil

AstraZeneca

Phase 3

2 2

Celebrex

PPhiladelphia Eye Associates

Phase 3

2 3

Psilocybin

COMPASS Pathways

Phase 3

11 4

Levophed

GGeneral Hospital of Ningxia Medical University

Bupropion XL

1 6

Desvenlafaxine SR

Pfizer

Phase 3

13 7

SPD489

Takeda

Phase 3

3 8

Venlafaxine ER

Pfizer

Phase 3

2 9

MK0869, Aprepitant

Merck & Co.

Phase 3

4 10

Antidepressant Therapy

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Postherpetic Neuralgia

NCT06708416

Clinical

Trials by Indication[1]

Postherpetic Neuralgia1 trial

A Study of ONO-1110 in Patients With Postherpetic Neuralgia

Active, not recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 2·NCT06708416·140 enrolled

Major Depressive Disorder (MDD)1 trial

A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Major Depressive Disorder

Completed· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 2·NCT06792136·103 enrolled

Social Anxiety Disorder (SAD)1 trial

A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Social Anxiety Disorder

Completed· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 2·NCT06805565·115 enrolled

Fibromyalgia1 trial

A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Fibromyalgia

Completed· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 2·NCT06752590·175 enrolled

Hunner Type Interstitial Cystitis1 trial

A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Hunner Type Interstitial Cystitis

Completed· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 2·NCT06752603·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ONO-1110. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ONO-1110 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ONO-1110. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ono Pharmaceutical Co. Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Ono Pharmaceutical Co. Ltd

ONO-1110

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Postherpetic Neuralgia1 trial

Major Depressive Disorder (MDD)1 trial

Social Anxiety Disorder (SAD)1 trial

Fibromyalgia1 trial

Hunner Type Interstitial Cystitis1 trial

References

Drug Info

Quick Facts

Related News